Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterLetter

Rituximab for Primary Angiitis of the Central Nervous System: Report of 2 Patients from the French COVAC Cohort and Review of the Literature

HUBERT DE BOYSSON, CAROLINE ARQUIZAN, LOIC GUILLEVIN and CHRISTIAN PAGNOUX
The Journal of Rheumatology December 2013, 40 (12) 2102-2103; DOI: https://doi.org/10.3899/jrheum.130529
HUBERT DE BOYSSON
Department of Internal Medicine, Centre Hospitalier Universitaire de la côte de Nacre, Caen; and Division of Internal Medicine, Hôpital Cochin, AP-HP, Université Paris-Descartes, Paris;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hubertdeboysson@yahoo.fr
CAROLINE ARQUIZAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LOIC GUILLEVIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTIAN PAGNOUX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Primary angiitis of the central nervous system (PACNS) is a rare and severe inflammatory disease affecting the vessels of the brain and sometimes spinal cord. Diagnosis relies on (1) a neurologic deficit that remains unexplained after complete examination; (2) CNS vascular abnormalities on conventional cerebral angiography (CCA) or histopathology; and (3) the exclusion of other differential diagnoses such as reversible cerebral vasoconstriction syndrome or systemic vasculitides1,2,3. Neurologic manifestations usually worsen or relapse in the absence of treatment. Corticosteroids are the cornerstone of therapy and with severe disease are often combined with an immunosuppressant, mainly cyclophosphamide (CYC). Few patients are refractory to this treatment and/or relapse. To date, only limited information exists on potential rescue and alternative treatments, including rituximab (RTX)4.

We describe 2 adult patients with PACNS who showed improvement with RTX and corticosteroids.

Case 1

In a 42-year-old man, progressive cerebellar ataxia developed over a couple of months; then left hemiparesis and binocular diplopia developed. Brain magnetic resonance imaging (MRI) revealed multiple lesions of the cortical and deep subcortical white matter, thalami, cerebellum, and cervical spine. Most lesions and meninges were enhanced after gadolinium injection (Figures 1A, B). Cerebrospinal fluid (CSF) examination revealed protein concentration 600 mg/l and leukocyte count 60/mm3. An open-wedge biopsy revealed a vascular wall lymphocytic infiltrate (Figure 1C). Complete examination (Table 1) was negative for differential diagnoses. Oral prednisone (70 mg/day) was administered with monthly intravenous CYC, but at 5 months, ataxia and upper-limb paresthesia worsened and the number of lesions on repeat MRI had increased. RTX was given (375 mg/m2/week for 4 weeks), followed by azathioprine. Neurological status improved 1 month after RTX completion, with reduced paresthesias and ataxia. Repeat brain and spine MRI showed fewer lesions (Figure 1D), without relapse at the 12-month followup post-RTX.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Images for Patient 1. (A, B) Magnetic resonance imaging (MRI) gadolinium-enhanced T1 sequences of brain and cervical spinal cord, respectively, showing lesions in cerebellar lobes as well as vermis, pons, subcortical white matter of anterior temporal lobes and cervical spine at C2 and C4 levels (arrows). C. Histopathology findings of brain biopsy (immunohistochemical staining of CD4+ and CD20+ cells) showing a lymphocytic infiltrate, predominantly CD4+ T cells, of the vessel wall. Staining for amyloid deposits was negative. D. MRI gadolinium-enhanced T1 sequence of brain demonstrating a reduced number of lesions after treatment with rituximab.

View this table:
  • View inline
  • View popup
Table 1.

Investigations performed in our 2 patients diagnosed with primary angiitis of the central nervous system.

Case 2

A 57-year-old woman developed balance disorder, dysarthria, focal motor deficit of the right arm, and progressive cognitive decline over 2 weeks. Brain MRI revealed recent and semirecent infarctions in anterior and middle cerebral artery territories. CCA revealed multiple and bilateral stenoses affecting the small arteries. CSF analysis showed protein concentration 700 mg/l and leukocyte count 17/mm3. Complete investigations (Table 1) were negative for differential diagnoses for PACNS. The patient received prednisone (70 mg/day) with RTX (375 mg/m2/week for 4 weeks) rather than CYC because of a history of bladder polyps. The neurologic status improved, and no new flares had occurred 20 months after RTX treatment. Repeat brain MRI revealed decreased size and number of fluid attenuated inversion recovery hyperintense signals.

PACNS is challenging to diagnose. Only a positive biopsy can ascertain the diagnosis, and all appropriate staining, immunohistochemistry studies, and immunophenotyping are needed to rule out related conditions such as amyloid-β–related angiitis or different mimicking diseases such as CNS lymphoma. However, in practice and for more than two-thirds of patients in previously referenced series, biopsy was not performed and diagnosis relied on the combination of vascular changes on CCA and the exclusion, after thorough clinical and laboratory evaluation, of other conditions that can involve brain vessels1,5,6,7,8. Our 2 patients underwent extensive investigations to rule out differential diagnoses. With a followup exceeding 1 year, brain imaging would not likely have shown amelioration of alternative diseases such as infection or intracranial atherosclerosis and under potent immunosuppressive regimens.

Although the optimal treatment for PACNS has not been determined, most patients achieve good outcomes with corticosteroids, with or without CYC2,3,8. Refractory and/or relapsing cases are rare, and require, after having reconsidered the diagnosis, alternative and/or rescue therapeutic options.

In antineutrophil cytoplasm antibody-associated vasculitides, RTX (a chimeric anti-CD20 antibody) was not inferior to CYC in inducing remission9. It was also effective for CNS involvement in some patients with granulomatosis with polyangiitis10. Recently, RTX treatment was successful in a 3-year-old girl with remitting-relapsing biopsy-proven PACNS after failure of corticosteroids, azathioprine, and CYC4. To our knowledge, our 2 cases represent the first reports suggesting the clinical and radiographic efficacy of RTX in adults diagnosed with PACNS.

Further reports and studies are needed to better determine the place of RTX in the treatment of PACNS refractory to corticosteroids and CYC or as an alternative to CYC for first-line therapy.

Acknowledgment

We thank Drs. Anthony Faivre and Guillaume Gondran for their participation in data collection; and Prof. Françoise Gray and Dr. Olivier Naggara for their help in reviewing biopsy samples and neuroimaging.

REFERENCES

  1. 1.↵
    1. Calabrese LH,
    2. Mallek JA
    . Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine 1988;67:20–39.
    OpenUrlPubMed
  2. 2.↵
    1. Néel A,
    2. Pagnoux C
    . Primary angiitis of the central nervous system. Clin Exp Rheumatol 2009;27:S95–107.
    OpenUrlPubMed
  3. 3.↵
    1. Salvarani C,
    2. Brown RD Jr..,
    3. Hunder GG
    . Adult primary central nervous system vasculitis. Lancet 2012;380:767–77.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. El M’Kaddem B,
    2. Clapuyt P,
    3. de Bruycker JJ,
    4. Lauwerys B,
    5. Raftopoulos C,
    6. Godfraind C,
    7. et al.
    Primary cerebral arteritis in a young girl: an unusual cause of acute recurrent neurological deterioration. Eur J Paediatr Neurol 2012;16:196–9.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Salvarani C,
    2. Brown RD Jr..,
    3. Calamia KT,
    4. Christianson TJ,
    5. Weigand SD,
    6. Miller DV,
    7. et al.
    Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 2007;62:442–51.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Benseler SM,
    2. Silverman E,
    3. Aviv RI,
    4. Schneider R,
    5. Armstrong D,
    6. Tyrrell PN,
    7. et al.
    Primary central nervous system vasculitis in children. Arthritis Rheum 2006;54:1291–7.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Birnbaum J,
    2. Hellmann DB
    . Primary angiitis of the central nervous system. Arch Neurol 2009;66:704–9.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Hajj-Ali RA,
    2. Singhal AB,
    3. Benseler S,
    4. Molloy E,
    5. Calabrese LH
    . Primary angiitis of the CNS. Lancet Neurol 2011;10:561–72.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Stone JH,
    2. Merkel PA,
    3. Spiera R,
    4. Seo P,
    5. Langford CA,
    6. Hoffman GS,
    7. et al.
    Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–32.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Holle JU,
    2. Gross WL
    . Neurological involvement in Wegener’s granulomatosis. Curr Opin Rheumatol 2011;23:7–11.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 12
1 Dec 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rituximab for Primary Angiitis of the Central Nervous System: Report of 2 Patients from the French COVAC Cohort and Review of the Literature
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rituximab for Primary Angiitis of the Central Nervous System: Report of 2 Patients from the French COVAC Cohort and Review of the Literature
HUBERT DE BOYSSON, CAROLINE ARQUIZAN, LOIC GUILLEVIN, CHRISTIAN PAGNOUX
The Journal of Rheumatology Dec 2013, 40 (12) 2102-2103; DOI: 10.3899/jrheum.130529

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Rituximab for Primary Angiitis of the Central Nervous System: Report of 2 Patients from the French COVAC Cohort and Review of the Literature
HUBERT DE BOYSSON, CAROLINE ARQUIZAN, LOIC GUILLEVIN, CHRISTIAN PAGNOUX
The Journal of Rheumatology Dec 2013, 40 (12) 2102-2103; DOI: 10.3899/jrheum.130529
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Case 1
    • Case 2
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • ASAS Health Index as an Addition to Routine Clinical Practice
  • Absence of Severe Complications From SARS-CoV-2 Infection in Children With Rheumatic Diseases Treated With Biologic Drugs
  • Dr. Kiltz, et al reply
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire